Galectin Therapeutics Inc. (GALT)

Over the past six months, Galectin Therapeutics' stock price has experienced fluctuations. As of April 10, 2026, the stock price had increased, but GALT shares have decreased since the beginning of the year. The company reported its 2025 financial results and launched an ATM program with H.C. Wainwright. Galectin Therapeutics received an upgrade to a Zacks Rank #2 (Buy).

Information regarding demand seasonality for Galectin Therapeutics, Inc.'s products and services is not explicitly available. Demand for its potential products would likely be driven by medical need, regulatory approvals, and market adoption rather than traditional seasonal consumer patterns.

Galectin Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on drug research and development within the biotechnology sector. The company aims to create therapies for fibrotic diseases, severe skin conditions, and cancer. Their lead drug, belapectin, is being developed for MASH with cirrhosis and portal hypertension and is being explored for cancer immunotherapy.

Galectin Therapeutics, Inc. is headquartered in Norcross, Georgia, United States, and maintains a laboratory-based research and development effort in the Boston area.

Galectin Therapeutics has a generally positive news sentiment score. Analyst ratings are mixed, with a consensus rating of "Hold", but at least one analyst has issued a "Strong Buy" rating. The upgrade to a Zacks Rank #2 (Buy) suggests an improving business trend. The oversubscription of the NAVIGATE trial suggests confidence in the drug's potential, while a substantial net loss and concerns regarding belapectin's results could negatively affect reputation.

Galectin Therapeutics' ownership is a mix of institutional, insider, and retail investors. Institutional investors hold approximately 10.58% of the stock, insiders hold 28.21%, and retail investors hold 61.20%. Major institutional shareholders include Vanguard Group Inc and BlackRock, Inc. Richard E. Uihlein holds the most shares among individual investors.